IL289231A - Salts of compounds, their crystalline forms and their uses - Google Patents

Salts of compounds, their crystalline forms and their uses

Info

Publication number
IL289231A
IL289231A IL289231A IL28923121A IL289231A IL 289231 A IL289231 A IL 289231A IL 289231 A IL289231 A IL 289231A IL 28923121 A IL28923121 A IL 28923121A IL 289231 A IL289231 A IL 289231A
Authority
IL
Israel
Prior art keywords
salts
compound
preparation
application
method therefor
Prior art date
Application number
IL289231A
Other languages
English (en)
Hebrew (he)
Inventor
Yin Lei
Yao Zhenglin
Original Assignee
Gan & Lee Pharmaceuticals Co Ltd
Yin Lei
Yao Zhenglin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=74040655&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL289231(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gan & Lee Pharmaceuticals Co Ltd, Yin Lei, Yao Zhenglin filed Critical Gan & Lee Pharmaceuticals Co Ltd
Publication of IL289231A publication Critical patent/IL289231A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL289231A 2019-06-21 2021-12-21 Salts of compounds, their crystalline forms and their uses IL289231A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201910542355 2019-06-21
PCT/CN2020/097482 WO2020253875A1 (zh) 2019-06-21 2020-06-22 一种化合物的盐、其晶型以及制备方法与应用

Publications (1)

Publication Number Publication Date
IL289231A true IL289231A (en) 2022-02-01

Family

ID=74040655

Family Applications (1)

Application Number Title Priority Date Filing Date
IL289231A IL289231A (en) 2019-06-21 2021-12-21 Salts of compounds, their crystalline forms and their uses

Country Status (16)

Country Link
US (1) US20220168302A1 (enExample)
EP (1) EP3988546A4 (enExample)
JP (1) JP2022538076A (enExample)
KR (1) KR20220041090A (enExample)
CN (1) CN115708409A (enExample)
AR (1) AR119184A1 (enExample)
AU (1) AU2020296048A1 (enExample)
BR (1) BR112021025944A2 (enExample)
CA (1) CA3144546A1 (enExample)
CL (1) CL2021003438A1 (enExample)
CO (1) CO2022000502A2 (enExample)
IL (1) IL289231A (enExample)
MX (1) MX2022000051A (enExample)
PH (1) PH12021553151A1 (enExample)
WO (1) WO2020253875A1 (enExample)
ZA (1) ZA202200964B (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022042738A1 (zh) * 2020-08-31 2022-03-03 甘李药业股份有限公司 一种含cdk4/6抑制剂的药物组合物
US20250332167A1 (en) * 2021-05-17 2025-10-30 Gan & Lee Pharmaceuticals Co., Ltd. Pharmaceutical use of cdk 4/6 inhibitor
EP4696689A1 (en) * 2023-04-04 2026-02-18 Suzhou Kintor Pharmaceuticals, Inc. Salt form and crystal form of chiral heterocyclic compound having hedgehog pathway antagonist activity

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK9742002A3 (en) * 2000-01-07 2003-02-04 Transform Pharmaceuticals Inc High-throughput formation, identification, and analysis of diverse solid-forms
CN106810536A (zh) * 2015-11-30 2017-06-09 甘李药业股份有限公司 一种蛋白激酶抑制剂及其制备方法和医药用途

Also Published As

Publication number Publication date
CA3144546A1 (en) 2020-12-24
EP3988546A4 (en) 2023-05-17
EP3988546A1 (en) 2022-04-27
AR119184A1 (es) 2021-12-01
KR20220041090A (ko) 2022-03-31
MX2022000051A (es) 2022-05-24
CO2022000502A2 (es) 2022-01-28
US20220168302A1 (en) 2022-06-02
AU2020296048A1 (en) 2022-02-10
BR112021025944A2 (pt) 2022-02-08
CN115708409A (zh) 2023-02-21
PH12021553151A1 (en) 2022-07-25
WO2020253875A1 (zh) 2020-12-24
CL2021003438A1 (es) 2022-09-30
JP2022538076A (ja) 2022-08-31
ZA202200964B (en) 2022-08-31

Similar Documents

Publication Publication Date Title
SG11202106706TA (en) Heterocyclic compound intermediate, preparation method therefor and application thereof
ZA201907687B (en) Salt of an aminopyridine derivative compound, a crystalline form thereof, and a process for preparing the same
EP3275883A4 (en) Method for producing novel nitrogen-containing compound or salt thereof, and production intermediate of same
IL311631B1 (en) Polymorphic form of a kinase inhibitor preparation, a pharmaceutical preparation containing the same and a method for its preparation and use
IL288348A (en) Synthesis method of furoimidazopyridine compound, crystal form of furoimidazopyridine compound, and crystal form of salt thereof
IL288349A (en) Method for synthesizing furoimidazopyridine compound, polymorphic substance and polymorphic substance of salt
EP3763713A4 (en) CRYSTAL FORM AND SALT FORM OF A PYRIDOIMIDAZOLE COMPOUND AND THE METHOD FOR MANUFACTURING IT
HUE062473T2 (hu) Updacitinib só vegyület és eljárás elõállítására
IL291114A (en) A pyrimidine compound and a method for its preparation
EP3677575A4 (en) CRYSTALLINE FORM OF OZANIMODHYDROCHLORIDE AND PRODUCTION METHOD THEREFOR
ZA202200964B (en) Salts of a compound, crystal forms of the salts and preparation method and use thereof
IL276430A (en) A pharmaceutical compound, its cures, its formulations, and methods for its preparation and use
EP3530650A4 (en) CRYSTALLINE FORM OF (R) -4-HYDROXY-2-OXO-1-PYRROLIDINE ACETAMIDE, PRODUCTION METHOD THEREFOR, AND USE THEREOF
EP3252065A4 (en) Crystals of n-acetylneuraminic acid ammonium salt anhydrate, and method for producing same
IL288285A (en) Crystalline form of sofpironium bromide and preparation method thereof
EP3842426A4 (en) PREPARATION PROCESS OF PYRROLO-AMINO-PYRIDAZINONE COMPOUNDS AND INTERMEDIATE THEREOF
EP3842438A4 (en) PROCESS FOR THE PREPARATION OF ECCEINASCIDINE COMPOUND AND AN INTERMEDIATE THEREOF
HK1255014A1 (zh) 制备取代5，6-二氢-6-苯基苯并[f]异喹啉-2-胺的方法
IL282817A (en) New material, production method, and its use
IL281168A (en) Crystal forms of the quinazole compound and its hydrochloride salts
IL290625A (en) Crystalline forms of quinoline analogs and their salts, compositions, and methods of their use
ES3065261T3 (en) Crystalline form of a multi-tyrosine kinase inhibitor, method of preparation, and use thereof
EP4067345A4 (en) CRYSTALLINE FORM OF ACETYLCHOLINESTERASE INHIBITOR AND PREPARATION METHOD AND APPLICATION THEREOF
GB201918401D0 (en) Novel crystalline forms of Flufenacet, methods for their preparation and use of the same
GB201918391D0 (en) Novel crystalline forms of flufenacet, methods for their preparation and use of the same